A federal judge in San Diego has rejected claims by some 1,500 plaintiffs in a multidistrict litigation that several similar type 2 diabetes drugs increase the risk of pancreatic cancer.
U.S. District Judge Anthony Battaglia on Tuesday granted summary judgment to AstraZeneca PLC’s Amylin Pharmaceuticals, Eli Lilly and Co, Merck & Co Inc and Novo Nordisk Inc, finding the plaintiffs’ claims preempted by federal law.
To read the full story on Westlaw Today, click here: bit.ly/2OjtpIJ
Our Standards: The Thomson Reuters Trust Principles.